LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday it received "further positive" data from its Dreamm-1 study of patients with relapsed multiple myeloma.
Multiple myeloma is the second most common blood cancer in the US and is generally considered treatable but not curable, according to GSK. Multiple myeloma commonly becomes refractory to available treatments. GSK said "research into new treatments is vital".
The patients received the treatment GSK2857916, with 60% achieving an overall response rate. The response rate was identical to the rate reported a year ago, which GSK believes demonstrates "not only the potential efficacy of the medicine but the durability and depth of response".
The number of patients achieving a complete response increased 15% over the interim report. The median progression-free survival was 12 months from the previously reported 7.9 months.
"These data are very encouraging and I am excited by what they could mean for people living with multiple myeloma. We are aggressively advancing this potential new medicine and plan to have pivotal data to support its filing by the end of this year," Chief Scientific Officer & President of R&D Hal Barron.
Shares in GSK closed up 2.7% Thursday at 1,566.00 pence each.
Glaxosmithkline (GSK)